SELECT-AXIS 2 trial demonstrated efficacy and safety of upadacitinib in treatment of non-radiographic axSpA. ASAS40 at week 14 (45% vs. 23% placebo). No MACE, VTEs, IBD, death. @RheumNow #EULAR2022 ABST#OP0016 https://t.co/vyky0JJJjS

Combination tx of NSAIDs and TNFi (celecoxib and golimumab) did not show significant superiority compared to TNFi alone in slowing radiographic progression for treatment of radiographic axSpA. There was a numerical reduction however. #EULAR2022 @RheumNow #ABSTOP0018 https://t.co/gUZAwd92dK